Loading company…
Signet Therapeutics researches and develops targeted cancer drugs and related technologies.
Founded in 2020 and based in Shenzhen, Signet Therapeutics develops cancer medicines and biomedical technologies, with research centers in Shenzhen and Boston. Its disease model platform addresses stomach, bowel, lung and breast cancers. In January 2026, it raised CNY 80 million in Series A funding to advance SIGX1094 trials and support development of SIGX2649.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in